Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways
Objective: The present study aimed to assess the effects of citral nanoliposome on Parkinson's treatment in a rat model. Background: Parkinson's disease is the most…Serum levels of IL-1β and interleukin 6 in Parkinson’s disease
Objective: We aim to assess IL-1 β and IL-6 serum levels in patients with PD and in controls and to explore their associations with clinical…LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway
Objective: Analyzing the mechanism of inflammatory response induced by oligomeric α-synuclein (O-αS) in LRRK2 G2019S mutation astrocytes to provide new targets and ideas for the…Associations of IL-1β and IL-6 gene polymorphisms with Parkinson’s disease(PD)
Objective: We aim to explore the associations of IL-1β and IL-6 gene polymorphisms with the pathogenesis of PD and with clinical features of motor and…Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.
Objective: To investigate the neuroprotective role of honey against oxidative stress and neuroinflammation induced by MPTP in adult male Swiss mice. Background: Oxidative stress and…The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease
Objective: The aim of this study is to explore the function and mechanism of RNA m6A modification in gut-derived inflammation of Parkinson's disease (PD). Background:…LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia
Objective: This study explores the inflammatory processes in leucine-rich repeat kinase 2 (LRRK2)- microglia carrying the G2019S mutation and determines their contribution to Parkinson’s disease…Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment
Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity
Objective: We aimed to investigate biomarkers of inflammation and neuroaxonal damage in people with isolated REM sleep behaviour disorder (iRBD) compared to controls, and understand…Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 25
- Next Page »